{
  "image_filename": "table_p7_det_6_004.png",
  "image_path": "Hsiao_et_al.__2023_/extracted/figures/table_p7_det_6_004.png",
  "image_type": "Table",
  "page_number": 7,
  "block_id": "det_6_004",
  "claim_id": "claim_006",
  "claim": "Flublok is produced using a novel production platform in which recombinant HA is expressed in insect cells using a baculovirus expression vector system (BEVS).",
  "supports_claim": false,
  "explanation": "Table presenting demographic and clinical characteristics (sex, race/ethnicity, coexisting illnesses, receipt of previous influenza vaccine) of participants receiving a recombinant vaccine versus a standard-dose vaccine and all vaccinees. The table provides participant demographics and clinical characteristics and contains no information on how Flublok is produced, so it does not support the claim.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Table presenting demographic and clinical characteristics (sex, race/ethnicity, coexisting illnesses, receipt of previous influenza vaccine) of participants receiving a recombinant vaccine versus a standard-dose vaccine and all vaccinees.",
    "evidence_found": null,
    "reasoning": "The table provides participant demographics and clinical characteristics and contains no information on how Flublok is produced, so it does not support the claim.",
    "confidence_notes": null
  }
}